224 related articles for article (PubMed ID: 37515657)
1. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
Nishimura JI; Kawaguchi T; Ito S; Murai H; Shimono A; Matsuda T; Fukamizu Y; Akiyama H; Hayashi H; Nakano T; Maruyama S
Int J Hematol; 2023 Oct; 118(4):419-431. PubMed ID: 37515657
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Ariceta G
Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
Socié G; Caby-Tosi MP; Marantz JL; Cole A; Bedrosian CL; Gasteyger C; Mujeebuddin A; Hillmen P; Vande Walle J; Haller H
Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
6. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.
Usuki K; Ikezoe T; Ishiyama K; Kanda Y; Gotoh A; Hayashi H; Shimono A; Kitajima A; Obara N; Nishimura JI
Int J Hematol; 2023 Sep; 118(3):311-322. PubMed ID: 37477863
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab in pregnancy: a narrative overview.
Sarno L; Tufano A; Maruotti GM; Martinelli P; Balletta MM; Russo D
J Nephrol; 2019 Feb; 32(1):17-25. PubMed ID: 30159857
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan.
Ikezoe T; Noji H; Ueda Y; Kanda Y; Okamoto S; Usuki K; Matsuda T; Akiyama H; Shimono A; Yonemura Y; Kawaguchi T; Chiba S; Kanakura Y; Nishimura JI; Ninomiya H; Obara N
Int J Hematol; 2022 Apr; 115(4):470-480. PubMed ID: 35146630
[TBL] [Abstract][Full Text] [Related]
10. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Wong EK; Kavanagh D
Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
[TBL] [Abstract][Full Text] [Related]
11. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
Ninomiya H; Obara N; Chiba S; Usuki K; Nishiwaki K; Matsumura I; Shichishima T; Okamoto S; Nishimura JI; Ohyashiki K; Nakao S; Ando K; Kanda Y; Kawaguchi T; Nakakuma H; Harada D; Akiyama H; Kinoshita T; Ozawa K; Omine M; Kanakura Y
Int J Hematol; 2016 Nov; 104(5):548-558. PubMed ID: 27464489
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.
Ito S; Hataya H; Ashida A; Hamada R; Ishikawa T; Ishikawa Y; Shimono A; Konomoto T; Miyazawa T; Ogura M; Tanaka K; Kagami S
Nephrol Dial Transplant; 2023 Feb; 38(2):414-424. PubMed ID: 35438790
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
Patriquin CJ; Kuo KHM
Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
[TBL] [Abstract][Full Text] [Related]
14. [New Complement Therapeutics in Complement-Related Diseases].
Wakamiya N; Ohtani K; Hidaka Y; Inoue N
Brain Nerve; 2019 Jun; 71(6):555-564. PubMed ID: 31171752
[TBL] [Abstract][Full Text] [Related]
15. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
16. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
17. Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD.
McBride HJ; Frazer-Abel A; Thiemann S; Lehto SG; Hutterer KM; Liu J
Ann Hematol; 2023 Dec; 102(12):3299-3309. PubMed ID: 37817009
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.
Murai H; Suzuki S; Hasebe M; Fukamizu Y; Rodrigues E; Utsugisawa K
Ther Adv Neurol Disord; 2021; 14():17562864211001995. PubMed ID: 33796147
[TBL] [Abstract][Full Text] [Related]
19. Current and future pharmacologic complement inhibitors.
Risitano AM
Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
[TBL] [Abstract][Full Text] [Related]
20. Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan.
Tanimoto T; Kusumi E; Hosoda K; Kouno K; Hamaki T; Kami M
Orphanet J Rare Dis; 2014 Apr; 9():48. PubMed ID: 24716834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
